GENEVA/LONDON, Oct 23 (Reuters) - The world's first malariavaccine is promising but should be used on a pilot basis beforeany wide-scale use, given its limited efficacy, World HealthOrganization experts said on Friday.
The Mosquirix shot, made by GlaxoSmithKline, couldpotentially help stop millions of cases of malaria in babies andyoung children in Africa at risk of the deadly mosquito-bornedisease. However, it is less effective than vaccines againstmany other diseases. (Reporting by Ben Hirschler; Editing by David Holmes)
Glaxosmithkline (GSK)